A new maintenance regimen has been shown to increase survival for people with newly diagnosed advanced ovarian cancer who were disease-free after surgery or responded to first-line platinum-based chemotherapy. The regimen, a combination of the PARP inhibitor olaparib and bevacizumab, was reported at the 2022 European Society for Medical Oncology Congress.

“The overall survival advantage offered by the combination of olaparib and bevacizumab is sizable and warrants defining this combination as the new standard of care for patients with advanced-stage, high-grade ovarian carcinoma with platinum-sensitive disease,” Eva Chalas, MD, physician director of Perlmutter Cancer Center at NYU Langone Hospital—Long Island and professor in the Department of Obstetrics and Gynecology at NYU Long Island School of Medicine, tells Healio HemOnc Today.

Read more from Healio HemOnc Today.